Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference
Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner will present at the AD/PD™ Conference in Barcelona from March 15-20, 2022. The presentation will cover results from preclinical and Phase 1 studies of IkT-148009, a selective Abelson Tyrosine Kinase inhibitor for Parkinson's disease. Results indicate IkT-148009 clears alpha-synuclein aggregates, protects neurons, and shows no significant adverse events across 88 subjects. The company plans to initiate a Phase 2 study in Q2 2022, further validating the therapeutic potential of IkT-148009 as a disease-modifying treatment.
- Successful preclinical results indicating neuronal protection and functional recovery.
- Phase 1 study demonstrated no clinically significant adverse events and effective CNS penetration.
- Upcoming Phase 2 study set to start in Q2 2022, signaling progress in treatment development.
- None.
BOSTON and ATLANTA, March 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will give an oral presentation at the AD/PD™, Alzheimer's & Parkinson's Diseases Conference being held in Barcelona, Spain from March 15-20, 2022.
Dr. Werner will discuss the results from the Company's preclinical, Phase 1and Phase 1b studies of its highly selective Abelson Tyrosine Kinase inhibitor IkT-148009 for the treatment of Parkinson's disease. In preclinical animal models, IkT-148009 has demonstrated the ability to clear alpha-synuclein aggregates from the brain and GI tract, protect neurons from degeneration, may promote regeneration of neurons, and induce substantial functional recovery in measures of motor and non-motor function. The Phase 1 study, which was initiated in February 2021, demonstrated high levels of drug exposure in the blood with no clinically significant adverse events observed across 88 subjects in single and/or 7-day dosing up to 250 mg. Penetration into the central nervous system was confirmed by measures of IkT-148009 in the spinal fluid. In the ongoing Phase 1b study in mild to moderately advanced Parkinson's patients (Hoehn & Yahr scale ≤ 3.0), no clinically meaningful adverse events have been observed and the Company will provide an update on safety and pharmacokinetics of IkT-148009 in patients. These promising results continue to validate the safety and therapeutic potential of IkT-148009 as a potential disease-modifying treatment for Parkinson's disease. Inhibikase expects to initiate a Phase 2 study for IkT-148009 in the second quarter of 2022.
Details for the presentation are below:
Alzheimer's & Parkinson's Diseases Conference:
Presentation: Parkinson's Disease Modification Through Abl Kinase Inhibition
Date: Friday, March 18, 2022
Time: 5:45 PM - 6:00 PM
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, or MSA, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-phase-11b-clinical-data-at-the-upcoming-adpd-alzheimers--parkinsons-diseases-conference-301496999.html
SOURCE Inhibikase Therapeutics, Inc.
FAQ
What are the key results of IkT-148009 in the preclinical studies?
When will Inhibikase present its findings on IkT-148009?
What is the status of the Phase 1b study of IkT-148009?
What are the next steps for Inhibikase regarding IkT-148009?
What was the participant count in the Phase 1 study of IkT-148009?
